A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0148-0287 C(Insulin 287) at Steady State Conditions in Subjects With Type 1 Diabetes
Phase of Trial: Phase I
Latest Information Update: 23 May 2019
Price : $35 *
At a glance
- Drugs Insulin 287 (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 02 Dec 2018 Planned End Date changed from 21 Nov 2019 to 8 Dec 2019.
- 02 Dec 2018 Status changed from not yet recruiting to recruiting.
- 06 Nov 2018 New trial record